Despite the increasing accessibility to preclinical AD biomarkers, such as amyloid and tau positron emission tomography (PET) as well as amyloid beta, tau and phosphorylated-tau levels in the cerebrospinal fluid (CSF), screening among individuals with normal cognition remains expensive and ineffective [3]. Here, MAPT is linked to Alzheimer disease.